CING · Cingulate Inc.
$5.05
+0.11 (+2.23%)
At close · Aug 6
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company can give no assurance that its plans will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events noted above, which results in substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$67.04M
Shares
13.28M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$22.45M
-44.4%
FY2025
Diluted EPS
-$4.44
+56.5%
FY2025
Operating Cash Flow
-$17.25M
+6.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | -$1.36M | — | — | — | — | |
| $9.74M | $9.77M | $9.45M | $15.49M | $9M | $8.41M | |
| $14.42M | $10.16M | $6.2M | $7.27M | $8.51M | $12.27M | |
| -$24.16M | -$19.94M | -$15.64M | -$22.76M | -$17.5M | -$20.68M | |
| $633.75K | — | — | $790K | $292.34K | — | |
| -$731.97K | — | $99.24K | -$775.76K | -$174.51K | -$30.59K | |
| -$27.91M | -$22.45M | -$15.55M | -$23.53M | -$17.68M | -$20.71M | |
| -$27.71M | -$22.45M | -$15.55M | -$23.53M | -$17.68M | -$20.71M | |
| — | — | — | — | — | -$20.71M | |
| USD/shares | — | -$4.44 | -$10.20 | -$312.00 | -$374.40 | — |
| USD/shares | — | -$4.44 | -$10.20 | -$312.00 | — | — |
| shares | — | 5.06M | 1.52M | 75.44K | 47.12K | 30.89K |
| shares | — | 5.06M | 1.52M | 75.44K | — | 30.89K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.06×
EV/EBIT
—
Peer median 48.34×
P/E (TTM)
—
Peer median 3.46×
Peer medians compare against the 291 similar-size Biotechnology companies (of 521 listed).